IR-Med Inc.
IRME · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.28 | 0.33 | -0.03 | -0.28 |
| FCF Yield | -4.21% | -4.05% | -10.14% | -1.81% |
| EV / EBITDA | -17.59 | -16.20 | -6.54 | -37.11 |
| Quality | ||||
| ROIC | 1,416.79% | -869.20% | -331.87% | -144.42% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.73 | 0.66 | 0.71 | 0.67 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 57.14% | 5.58% | -36.29% | -525.12% |
| Safety | ||||
| Net Debt / EBITDA | -0.01 | 0.12 | 0.57 | 0.72 |
| Interest Coverage | -647.00 | 0.00 | -793.67 | -735.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.84 | 0.00 |
| Cash Conversion Cycle | -1,008.10 | -1,331.18 | -1,936.51 | -4,234.00 |